Tumor-associated pDCs can be reprogrammed to their anti-tumor function upon appropriate re-activation with TLR-7 and TLR-9 agonists [78,79,80,81], and numerous clinical trials (phase I-III) are ongoing (Clinicaltrials.gov study identifiers: NCT02644967, NCT03445533, NCT03052205, NCT03084640, NCT03618641, NCT02680184, NCT03831295, and NCT02521870). The gene discussed is TLR9; the disease is neoplasm.